Biofrontera

Biofrontera, Inc. is a biopharmaceutical company, which engages in the commercialization of pharmaceutical products. It specializes in the treatment of dermatological conditions, caused primarily by exposure to sunlight that results in sun damage to the skin. The company is focused on the treatment of actinic keratosis and markets a topical antibiotic for treatment of impetigo. Its products include Ameluz and Xepi, its two prescription drugs, and BF-RhodoLED, a lamp used with Ameluz, for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company was founded on March 3, 2015 and is headquartered in Woburn, MA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biofrontera reports Q1 recovery post cyberattack, eyes product expansion

Biofrontera Inc. navigated challenges in Q1 2024, with a cyberattack impacting revenues, but recovery and growth were evident by April 30, 2024.
The company's strategic strengths lie in cost reduction through renegotiations, successful fundraising efforts, and advancements in clinical trials and product development.
Opportunities abound for Biofrontera with upcoming product launches, FDA approvals, and a focus on operational efficiency and financial management to drive future profitability.
Addressing financial challenges and leveraging opportunities will be key for Biofrontera to sustain growth, enhance market position, and deliver value to stakeholders in the coming quarters.

Biofrontera reports robust Q2 sales growth and cost efficiencies

Biofrontera delivered strong sales growth and cost management in Q2 2024, improving financial performance.
While challenges like net losses persist, opportunities exist to leverage momentum for sustained growth.
The company's focus on operational efficiency and revenue expansion sets the stage for future success and value creation.

Biofrontera reports steady Q3 growth amidst operational challenges and opportunities

Biofrontera Inc. showed resilience with revenue growth despite challenges like delayed deliveries.
Strategic strengths include FDA approvals, positive trial results, and focus on operational efficiency.
Challenges in high operating expenses and negative EBITDA highlight areas for improvement.
Opportunities lie in market expansion, clinical trial progress, and strategic financial management.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

WOBURN, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced the completion of a private placement of a $4.2 million senior secured convertible note (the “Note”) with its principal shareholders.

Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note

Biofrontera Inc. (NASDAQ:BFRI ) Q3 2024 Earnings Conference Call November 14, 2024 10:00 AM ET Company Participants Andrew Barwicki - Investor Relations Hermann Luebbert - Chief Executive Officer, Chairman and Founder Fred Leffler - Chief Financial Officer Conference Call Participants Jonathan Aschoff - ROTH Capital Bruce Jackson - The Benchmark Company Operator Welcome to the Biofrontera Inc. Third Quarter 2024 Financial Results and Business Update Conference Call. [Operator Instructions] Please note this event is being recorded.

Biofrontera Inc. (BFRI) Q3 2024 Earnings Call Transcript

Biofrontera Inc. (BFRI) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compares to loss of $4.64 per share a year ago.

Biofrontera Inc. (BFRI) Reports Q3 Loss, Lags Revenue Estimates

WOBURN, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today reported financial results for the three and nine months ended September 30, 2024 and provided a business update.

Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update

WOBURN, MA / ACCESSWIRE / November 1, 2024 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of PDT, announces it will report financial results for the three and nine months ended September 30, 2024 on Wednesday, November 13, 2024. The results will be released after the market close on Wednesday, Nov 13 and the company will host a conference call on Thursday, November 14 at 10:00am Eastern Time.

Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024

WOBURN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of PDT, today announced top-line results in its Phase 3 study of the use of Ameluz® with the BF-RhodoLED® lamp in the treatment of sBCC (study ALA-BCC-CT013).

Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

WOBURN, Mass., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), announced today that the database for the treatment phase of study ALA-BCC-CT013 has been locked.

Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

WOBURN, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the commercialization of dermatologic products, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's sNDA to increase the maximally approved dosage from one to three tubes of Ameluz® per treatment.

FDA Approves Use of Up To Three Tubes of Biofrontera Inc.'s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment

WOBURN, MA / ACCESSWIRE / September 25, 2024 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatologic products, today announced that management will present at the 3rd Annual ROTH Healthcare Opportunities Conference to be held at the Metropolitan Club in New York, NY. Date: October 9, 2024 Time of Presentation: 12:30 - 1:10 PM ET Format: Live Presentation 1x1 Meetings: Please contact your Roth representative About Biofrontera Inc. Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics.

Biofrontera to Present at the 3rd Annual ROTH Healthcare Opportunities Conference

Biofrontera Inc. (NASDAQ:BFRI ) Q2 2024 Earnings Conference Call August 15, 2024 10:00 AM ET Company Participants Andrew Barwicki - Barwicki Investor Relations Hermann Luebbert - CEO, Chairman and Founder Fred Leffler - CFO Conference Call Participants Jonathan Aschoff - ROTH MKM Bruce Jackson - The Benchmark Company Operator Good day, and welcome to the Biofrontera Inc. Second Quarter 2024 Financial Results and Business Update Conference Call. All participants will be in a listen-only mode.

Biofrontera Inc. (BFRI) Q2 2024 Earnings Call Transcript

Woburn, MA, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, today reported financial results for the three and six months ended June 30, 2024 and provided a business update.

Biofrontera Inc. Reports Second Quarter 2024 Financial Results and Provides a Business Update

WOBURN, MA / ACCESSWIRE / August 9, 2024 / Biofrontera Inc. (Nasdaq:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three and six months ended June 30, 2024 on Wednesday, August 14, 2024. The results will be released after the market close on Wednesday, Aug 14 and the company will host a conference call on Thursday, August 15 at 10:00am Eastern Time.

Biofrontera Inc. to Report Second Quarter Financial Results on August 14, 2024

WOBURN, MA, June 24, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI), a biopharmaceutical company specializing in the commercialization of dermatologic products, is proud to announce the launch of its FDA-approved RhodoLED XL, a red light emitting LED lamp.

Biofrontera Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp

Biofrontera Inc. (NASDAQ:BFRI ) Q1 2024 Earnings Conference Call May 16, 2024 10:00 AM ET Company Participants Andrew Barwicki - Barwicki Investor Relations Hermann Luebbert - Chief Executive Officer, Chairman and Founder Fred Leffler - Chief Financial Officer Conference Call Participants Jonathan Aschoff - ROTH MKM Bruce Jackson - The Benchmark Company Operator Welcome to the Biofrontera Inc. First Quarter 2024 Financial Results and Business Update Conference Call. At this time, all participants are in listen-only mode.

Biofrontera Inc. (BFRI) Q1 2024 Earnings Call Transcript

Conference call begins at 10:00 a.m. Eastern time on Thursday, May 16, 2024 WOBURN, MA / ACCESSWIRE / May 15, 2024 / Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, today reported financial results for the three months ended March 31, 2024 and provided a business update.

Biofrontera Inc. Reports First Quarter 2024 Financial Results and Provides a Business Update

WOBURN, MA / ACCESSWIRE / May 6, 2024 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it will report financial results for the three months ended March 29, 2024 on Wednesday, May 15, 2024. The results will be released after the market close on Wednesday, May 15 and the company will host a conference call on Thursday, May 16 at 10:00am Eastern Time.

Biofrontera Inc. to Report First Quarter 2024 Financial Results on May 15, 2024

WOBURN, MA / ACCESSWIRE / May 3, 2024 / Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that the Board of Directors has met and certified that two criteria described in warrants to purchase Series B-3 Convertible Preferred Stock issued by the Company on February 22, 2024 (the "Warrants") have been fulfilled by the Company. The Warrants were issued pursuant to a private placement of securities in February 2024, and the exercise of the Warrants will trigger payments totaling $8 million (gross) to the Company.

Biofrontera Announces Achievement of Two Milestones Associated with Series B-3 Convertible Preferred Stock Warrants

WOBURN, MA / ACCESSWIRE / March 26, 2024 / Biofrontera, Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that its 2024 Annual Meeting of Stockholders will be held on June 12, 2024 and that the close of business on April 22, 2024 will be the record date for the determination of stockholders entitled to notice of and to vote at the 2024 Annual Meeting. The exact time and location of the 2024 Annual Meeting will be specified in the Company's proxy statement for the 2024 Annual Meeting.

Biofrontera Inc. Announces 2024 Annual Meeting of Stockholders and Deadlines for Submission of Stockholder Proposals

Agenus

Tonix Pharmaceuticals Hld

Here's the deal with stocks to turn $1,000 into $1 million: if you want to play, you gotta pay. I'm not just talking about the price of the securities themselves.

3 Mind-Blowing Stocks That Could Turn $1,000 Into $1 Million

Biofrontera Inc. (BFRI) Q4 2023 Earnings Call Transcript

(This release corrects the release that was posted earlier on March 15, 2024 to update the Consolidated Balance Sheets) Conference call begins at 10:00 a.m. Eastern time on Monday, March 18, 2024 WOBURN, MA / ACCESSWIRE / March 15, 2024 / Biofrontera, Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, today reported financial results for the three and twelve months ended December 31, 2023.

CORRECTION: Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update

Conference call begins at 10:00 a.m. Eastern time on Monday, March 18, 2024 WOBURN, MA / ACCESSWIRE / March 15, 2024 / Biofrontera, Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, today reported financial results for the three and twelve months ended December 31, 2023.

Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update

WOBURN, MA / ACCESSWIRE / March 8, 2024 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it will report financial results for the three and 12 months ended December 31, 2023 on Friday, March 15, 2024. The results will be released after the market close on Friday, March 15 and the company will host a conference call on Monday, March 18 at 10:00am Eastern Time.

Biofrontera Inc. to Report Fourth Quarter and Full Year 2023 Financial Results on March 15, 2024

Provides Corporate Update on Financing and Investor Relations Toronto, Ontario--(Newsfile Corp. - March 5, 2024) - Medicus Pharma Ltd. (TSXV: MDCX) (FSE: N46) ("Medicus" or the "Company") is pleased to announce the appointment of Erica Monaco as Chief Operating Officer.

Medicus Pharma Ltd. Announces Appointment of Erica Monaco as Chief Operating Officer

Company closed financing of $8.0 million with an additional $8.0 million second tranche tied to milestones for aggregate proceeds of $16 million gross priced at market per Nasdaq rules Funding and recent restructuring of supply agreement allow Biofrontera Inc to assume R&D activities and to support further commercial growth WOBURN, MA / ACCESSWIRE / February 23, 2024 / Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company") , a biopharmaceutical company specializing in the commercialization of dermatologic products, today announced that it has closed on a securities purchase agreement with healthcare-focused institutional investors led by Rosalind Advisors as of February 22, 2024. Pursuant to the securities purchase agreements, the Company issued to the purchasers (a) an aggregate $8.0 million in shares of the company's Series B-1 Convertible Preferred Stock and (b) warrants to purchase shares of the Company's Series B-3 Convertible Preferred Stock with an aggregate exercise price of $8.0 million exercisable until the earlier of (i) five days after achievement of certain operational and commercial milestones, expected in Q2 of 2024, the approval by the Company's shareholders of an increase in authorized shares and other proposals, and the effectiveness of a registration statement with the U.S. Securities and Exchange Commission covering the resale of the Common Stock underlying all shares of preferred stock that may be issued under the securities purchase agreement or (ii) the five-year anniversary of the issuance of the warrants.

News for Biofrontera Stock (BFRI)